Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

Both adolescents and adults saw improvements with the use of ruxolitinib or povorcitinib to treat their nonsegmental vitiligo. Nonsegmental vitiligo could be effectively treated by using either ...

A recent study shows a medicated cream called ruxolitinib is extremely effective in about one-third of patients. The cream is giving patients hope that even if they don't benefit from the ...

Ruxolitinib cream (Opzelura, Incyte Dermatology), a Janus kinase (JAK) inhibitor, has shown efficacy and safety among adolescents and adults with AD. Only four of the 71 patients in the study ...

THURSDAY, March 27, 2025 (HealthDay News) -- Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Combining the Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) with either navitoclax or pelabresib led ...

WILMINGTON, Del., March 08, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...